BUSINESS
Aster DM to build budget hospitals in Gulf to meet demand from insured workers
In an exclusive interview over phone from Dubai, Moopen told Moneycontrol that insurance coverage to workers increased volumes but also put pressure on margins, as insurance companies now started pushing for steep discounts on package rates.
BUSINESS
Bharat Biotech acquires Chiron Behring Vaccines from GSK for undisclosed amount
The acquisition allows Hyderabad-headquartered Bharat Biotech to become world's largest manufacturer of rabies vaccines.
BUSINESS
USFDA Form 483 points to repeat observations at Dr Reddy's Bachupally plant
Out of 11, four are repetitive observations made by the agency in its inspection in 2017, while one observation goes even back to 2015 inspection.
BUSINESS
Laurus Labs invests over $100 million on formulation biz
In an exclusive interview, Laurus Labs CEO Satyanarayana Chava said the drug maker has invested around Rs 750-800 crore on developing products and building factories.
BUSINESS
Sun Pharma up against challenges as it builds speciality biz in US
"We committed close to a $1 billion on specialty business, we have to justify that investment and produce returns," Dilip Shanghvi said in the company's earnings call on February 12.
BUSINESS
Delhi HC sets aside govt ban on Lupin's diabetes drugs
Gluconorm-PG is a triple combination of diabetes drugs Glimepiride, Metformin, Pioglitazone, with sales of around Rs 50 crore.
BUSINESS
Sun Pharma responds to SEBI queries on super-stockist Aditya Medisales, 2004 FCCB issue
MD Dilip Shanghvi assures investors that at no point of time Sun Pharma's minority shareholders were disadvantaged in transactions with Aditya Medisales
BUSINESS
Indian pharma lobby seeks removal of India from US patent violator list
IPA has drawn the attention of USTR to the rapid progress made by India on a number of fronts, which were cited by USTR while placing India on the Priority Watch List in 2018
BUSINESS
Pharma weekly wrap: Government to regulate medical devices along the lines of drugs
The government's decision will ensure that medical devices and implants used in India are safe and tested, by bringing all these devices under Indian drug regulator Central Drugs Standard Control Organisation (CDSCO).
BUSINESS
Lupin gets 2 USFDA observations for its Goa plant
Lupin's Goa site, along with Unit 2 manufacturing plant in Pithampur, Indore are under USFDA's warning letter since November 2017.
BUSINESS
Pharma entrepreneur Jayaram Chigurupati death case shifts to Hyderabad police, mystery deepens
According to police, Rakesh Reddy allegedly killed Chigurupati over non-repayment of Rs 5.8 crore loan he had given to the latter.
BUSINESS
Maharashtra to invite tenders worth Rs 2,000 crore for Jyotiba Phule health scheme
Since inception the state government has spent around Rs 5000 crore on premiums and 52 lakh people were benefited.
BUSINESS
Cipla to continue cost cutting via portfolio rationalisation, manufacturing network review
Cipla had exited certain low margin products from the portfolio of its subsidiary Invagen in US.
BUSINESS
Lupin expects better show in Q4FY19 led by US launch of Levothyroxine, Ranolazine
Ranolazine or Renexa used in treatment of chest pain is expected to be launched in Q4 has three months marketing exclusivity. Renexa sold by Gilead Sciences had sales of $758 million.
BUSINESS
The gripping story of pharma entrepreneur Jayaram Chigurupati who lost his fortune, and life
The deal with Ranbaxy made Chigurupati overnight billionaire. Flush with cash he went on to acquire and set up at least a dozen companies.
BUSINESS
The risk of Ayushman Bharat eating into other healthcare schemes looms large
What is worrying is that the allocations for health expenditure remained flat beyond Ayushman Bharat.
BUSINESS
Union Budget 2019 spooks pharma & healthcare cos as govt overlooks their demands
Some of their demands such as bringing down the corporate tax to 25 percent and resumption of 200 percent weighted deduction on R& D were overlooked
BUSINESS
Budget 2019: Spend on PM's pet scheme Ayushman Bharat jumps 167%
Excluding the Ayushman Bharat scheme, increase in health allocation is only 6 percent.
BUSINESS
Justice B N Srikrishna: the go-to man for the government and corporates
Justice Srikrishna shot to fame after his retirement when he headed the "Srikrishna Commission" that investigated the Bombay communal riots of 1992–93.
BUSINESS
Stern action against Chanda Kochhar a warning to India Inc, say corporate governance experts
JN Gupta, Managing Director of Stakeholders Empowerment Services feels the stern action against ICICI Bank's former chief Chanda Kochhar is a warning for other boards of the corporate world.
BUSINESS
Strides to ramp up sales in US, other regulated markets after Australia biz sale
Strides had a net debt of around Rs 1,820 crore as on December 31, 2018.
BUSINESS
Piramal Enterprises says housing loans to be 10% of advances by end-FY19
Loans to real estate developers which constituted about 78 percent in Q2FY19, has come down to 70 percent in Q3.
BUSINESS
Exclusive | Wockhardt confident of business taking off in 3-5 years aided by India, US and antibiotic portfolio launch
After a disastrous 2017-18, there are signs of recovery in FY19. In 9MFY19, sales grew 9 percent and net loss narrowed to Rs 180 crore from Rs 454 crore from last year.
BUSINESS
This week in Pharma: Government sends mixed signals on drug pricing
With elections just a few months away, it seems that the government may not want to side too much with the industry.
